
    
      This is a 2-part study: Part 1 is open-label, while Part 2 is a randomized, double-blind,
      placebo-controlled, multicenter study. The study will enroll participants with MDD for whom a
      physician has assessed to be at risk for suicide. The study will consist of a screening
      evaluation, a treatment period, and a safety follow-up period. Participants' safety will be
      evaluated throughout the study. If you or a loved one are having thoughts of suicide, please
      seek immediate medical help. Go to the emergency room or call the National Suicide Prevention
      Lifeline at 1-800-273-8255.
    
  